Keywords: satraplatin, fails, reach, efficacy, endpoint, ph, iii

Satraplatin fails to reach efficacy endpoint in Ph III trial

Article | 05 November 2007

Print This

German biopharmaceutical firm GPC Biotech AG has announced that its anticancer agent satraplatin has fallen short of its primary efficacy ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in